Novartis Unveils New Strategy Focused On US-First, Eight Blockbuster Brands

Novartis AG NVS has revealed insights into the updated company strategy. The company said that a 'US-first' mindset, increasing the share of U.S. patients in clinical trials, and building capability and talent, among other actions, will enable Novartis to achieve this objective.
Novartis' aspiration is "to improve competitive positioning and organically build its U.S. business to become a top-five player in the U.S. by 2027," it said in a statement.
In April, Novartis announced integrating its pharmaceuticals and oncology units into the Innovative Medicines business to simplify its structure, targeting savings of at least $1 billion by 2024. The transformation nears completion.
Also See: Novartis To Petition US Supreme Court To Uphold Patent Validity For Multiple Sclerosis Drug, Gilenya.
It stated that Novartis is also aiming to be a top-three player in China, a key growth market for the next decade, while maintaining leading positions in Germany and Japan.
Novartis announced a strategy based on eight big drug brands as the pharma giant reshapes itself following the decision to spin off its underperforming generics unit, Sandoz.
During the investor event, Novartis said the currently in-market brands - Cosentyx, Entresto, Zolgensma, Kisqali, Kesimpta, Leqvio, Pluvicto, and Scemblix - each held multibillion-dollar peak sales potential.
Novartis also said it would focus in the future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors, and hematology medicine.
The company confirmed its previous financial targets, "we will continue to deliver improved financials with +4% sales CAGR through 2027 and a core operating income margin ~40%+ in the mid-long term," it added.
Price Action: NVS shares are down 1.32% at $76.52 during the premarket session on the last check Thursday.
Photo Via Company

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga